DaVita (NYSE:DVA) Cut to Hold at Wall Street Zen

DaVita (NYSE:DVA) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other analysts also recently issued reports about the company. Truist Financial cut their target price on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Barclays boosted their price target on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Finally, Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Trading Down 3.2%

Shares of DVA opened at $187.18 on Friday. DaVita has a 12 month low of $101.00 and a 12 month high of $247.49. The firm’s 50 day moving average is $181.36 and its 200-day moving average is $176.50. The stock has a market capitalization of $11.94 billion, a PE ratio of 13.78, a P/E/G ratio of 0.50 and a beta of 0.80.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.57 by $0.25. DaVita had a negative return on equity of 215.05% and a net margin of 6.49%. The business had revenue of $3.58 billion during the quarter, compared to analysts’ expectations of $3.52 billion. During the same period in the previous year, the company posted $2.51 earnings per share. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. Equities research analysts predict that DaVita will post 14.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several hedge funds and other institutional investors have recently modified their holdings of DVA. CoreCap Advisors LLC boosted its stake in DaVita by 161.7% in the third quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after buying an additional 97 shares in the last quarter. Provenance Wealth Advisors LLC bought a new position in DaVita in the third quarter valued at about $30,000. Root Financial Partners LLC raised its stake in DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares in the last quarter. Compass Financial Management LLC acquired a new position in DaVita during the second quarter worth about $72,000. Finally, NewEdge Advisors LLC lifted its holdings in shares of DaVita by 66.4% in the second quarter. NewEdge Advisors LLC now owns 361 shares of the company’s stock worth $80,000 after acquiring an additional 144 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

More DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Strong quarterly beat: DaVita reported adjusted earnings of $3.82 per share, above the $3.57 FactSet consensus, while revenue rose 4.6% year over year to $3.58 billion, exceeding the $3.52 billion estimate. DaVita Q3 adjusted EPS earnings flash
• Positive Sentiment: Kidney Care and international growth supported results: Earnings increased sharply from the prior-year period, with reported net income attributable to common shareholders rising 48.3% to $222.9 million. The company’s integrated kidney care operations were highlighted as a key growth driver. DaVita Q3 earnings beat and growth
• Neutral Sentiment: Profitability was mixed: Operating profit declined 1.3% year over year to $499.3 million, suggesting that higher costs and margin pressure offset some of the revenue growth. Cash flow from operations also fell to $518.8 million, while capital spending totaled $159.5 million. DaVita Q3 2026 financial results
• Negative Sentiment: $62 million China charge weighed on sentiment: Reports indicate a charge related to China reduced the quality of the quarter’s headline beat and raised concerns about potential additional costs or operational issues. DaVita China charge and Q3 earnings
• Negative Sentiment: Additional overhangs include insider selling and a legal investigation: Recent data shows several insiders, including Berkshire Hathaway and DaVita executives, selling shares, while Pomerantz LLP announced an investigation on behalf of investors. Neither necessarily indicates wrongdoing, but both developments may add near-term uncertainty. Pomerantz DaVita investor investigation

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.